|
|
|
02.04.26 - 10:03
|
Innate Pharma Files Its 2025 Universal Registration Document (Document D′enregistrement Universel) and 2025 Form 20-f Annual Report (Business Wire)
|
|
|
MARSEILLE, France--(BUSINESS WIRE)--Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced the filing of its 2025 Universal Registration Document (Document d'enregistrement universel) for the year ending December 31, 2025 with the French market authority “Autorité des Marchés Financiers” (“AMF”) on April 1st, 2026. It can be downloaded (in French) on the Company's website and on the AMF's website.
The following documents are incorporated into the Universal Registration Document:
the annual financial report,
the annual management report,
the corporate governance report provided for under Article L. 225-37 of the French Commercial Code,
the report of Statutory Auditors.
The Company also announced today the filing of its Form 20-F annual report for the year ending December 31, 2025 with the United States Securities and Exchange Commission (“SEC”) on April 1st, 2026. It can be also be accessed on the Company's website and on ...
|
|
|
|
|
|
|
26.03.26 - 07:06
|
Innate Pharma Reports Full Year 2025 Financial Results and Business Update (Business Wire)
|
|
|
Lacutamab TELLOMAK-3 confirmatory Phase 3 trial in cutaneous T-cell lymphoma (CTCL) is planned for initiation in H2 2026, subject to non-dilutive financing options currently under negotiation, including pharma partnering and royalty structures
IPH4502 (Nectin-4 ADC) shows preliminary anti-tumor activity with favorable safety profile to date; Phase 1 cohort enrichment ongoing at active dose levels
Monalizumab PACIFIC-9 Phase 3 trial, partnered with AstraZeneca, continues to advance toward a planned H2 2026 data readout
IPH5201 (anti-CD39 antibody), partnered with AstraZeneca - Interim results of MATISSE Phase 2 trial in non-small cell lung cancer (NSCLC) have been selected for an oral presentation in one of the Clinical Trials Plenary Session Sessions at the AACR Annual Meeting 2026, on April 21
Cash position of €44.8 million1 as of December 31, 2025 with an anticipated cash runway until the end of Q3 2026
Conference call to be held today at 2:00 p.m. CET / 9:00 a.m. EDT
MARSEILLE, France--(BUSINESS WIRE...
|
|
|
19.03.26 - 07:06
|
Innate Pharma Announces Conference Call and Webcast for Full Year 2025 Financial Results (Business Wire)
|
|
|
MARSEILLE, France--(BUSINESS WIRE)--#Biotech--Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”), today announces that the Company will hold a conference call on Thursday, March 26, 2026 at 2 p.m. CET / 9 a.m. EDT, following the release of its financial results for the full year ending December 31, 2025.
Participants during the call will be:
Jonathan Dickinson, Chief Executive Officer
Sonia Quaratino, Executive Vice President, Chief Medical Officer
Yannis Morel, Executive Vice President, Chief Operating Officer
Stéphanie Cornen, Vice President, Investor Relations, Communication and Commercial Strategy
Frédéric Lombard, Senior Vice President, Chief Financial Officer
Details for the Virtual Event
The live webcast will be available at the following link:
https://events.q4inc.com/attendee/704730270
Participants may also join via telephone using the following registration link: https://events.q4inc.com/analyst/704730270?pwd=usHLLD39
This information can...
|
|
|
|
|
|
|
|
|
13.11.25 - 07:03
|
Innate Pharma Reports Third Quarter 2025 Business Update and Financial Results (Business Wire)
|
|
|
Following FDA clearance for confirmatory Phase 3 trial TELLOMAK-3, lacutamab is progressing toward Phase 3 initiation in H1 2026 and potential accelerated approval in Sézary syndrome
IPH4502 Nectin-4 ADC Phase 1 enrollment continues to progress well - pharmacologically active dose reached
Monalizumab PACIFIC-9 on track to deliver data in H2 2026
Cash position of € 56.4 million1 as of September 30, 2025, anticipated cash runway until end Q3-2026
Conference call to be held today at 2:00 p.m. CET / 8:00 a.m. ET
MARSEILLE, France--(BUSINESS WIRE)--#immunotherapy--Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced its business update and financial results for the first nine months of 2025.
“This quarter highlights strong execution across our key programs,” said Jonathan Dickinson, Chief Executive Officer of Innate Pharma. “With FDA clearance to initiate TELLOMAK-3, we are advancing lacutamab toward its confirmatory Phase 3 and pote...
|
|
|
|
|
|
|
05.11.25 - 07:06
|
Innate Pharma Announces Conference Call and Webcast for Third Quarter 2025 Results and Business Updates (Business Wire)
|
|
|
MARSEILLE, France--(BUSINESS WIRE)--#immunotherapy--Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that the Company will hold a conference call on Thursday, November 13, 2025, at 2 p.m. CET / 8 a.m. ET, to give an update on business progress during the third quarter of 2025.
Participants during the call will be:
Jonathan Dickinson, Chief Executive Officer
Sonia Quaratino, Executive Vice President, Chief Medical Officer
Yannis Morel, Executive Vice President, Chief Operating Officer
Stéphanie Cornen, Vice President, Investor Relation, Communication and Commercial Strategy
Frédéric Lombard, Senior Vice President, Chief Financial Officer
Details for the Virtual Event
The live webcast will be available at the following link: https://events.q4inc.com/attendee/424851735
Analysts may also join via telephone, click here to register.
This information can also be found on the Investors section of the Innate Pharma website, www.innate-phar...
|
|
|
|
|
17.09.25 - 07:06
|
Innate Pharma Reports First Half 2025 Business Update and Financial Results (Business Wire)
|
|
|
IPH4502 Nectin-4 ADC Phase 1 enrollment progressing well: Preclinical update and Trial In Progress presented at AACR Annual Meeting 2025 and ASCO 2025 Annual Meeting.
Lacutamab BTD and Phase 3 preparation: FDA Breakthrough Therapy Designation (BTD) in February 2025 based on long-term follow-up data from the TELLOMAK clinical study presented at ASCO Annual Meeting 2025. Preparation of the confirmatory Phase 3 trial protocol is close to completion, following discussions with the FDA and EMA.
Monalizumab: AstraZeneca Phase 3 PACIFIC-9 enrollment is completed and high level read-out is expected in H2 2026.
Strategic focus: Innate Pharma plans to prioritize its investment in what it believes are its highest-value clinical assets, IPH4502, lacutamab, and monalizumab (partnered with AstraZeneca); its preclinical research and development (R&D) efforts will focus on advancing the next ADCs toward development, leveraging its pipeline of innovative targets. In line with such strategic focus and its objectives, the C...
|
|
|
10.09.25 - 10:36
|
Innate Pharma Announces Conference Call and Webcast for First Half 2025 Financial Results and Business Update (Business Wire)
|
|
|
MARSEILLE, France--(BUSINESS WIRE)--#ANKET--Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”), today announced that the Company will hold a conference call on Wednesday, September 17, 2025, at 2 p.m. CEST / 8 a.m. EDT, to give an update on business progress during the first half of 2025.
Participants during the call will be:
Jonathan Dickinson, Chief Executive Officer
Sonia Quaratino, Executive Vice President, Chief Medical Officer
Yannis Morel, Executive Vice President, Chief Operating Officer
Frédéric Lombard, Senior Vice President, Chief Financial Officer
Details for the Virtual Event
The live webcast will be available at the following link:
https://events.q4inc.com/attendee/642492835
Participants may also join via telephone using the following registration link: https://registrations.events/direct/Q4I970472
This information can also be found on the Investors section of the Innate Pharma website, www.innate-pharma.com. A replay of the webcast wi...
|
|
|
02.09.25 - 07:03
|
Number of Shares and Voting Rights of Innate Pharma as of September 1, 2025 (Business Wire)
|
|
|
MARSEILLE, France--(BUSINESS WIRE)--#ANKET--Regulatory News:
Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or “AMF”) General Regulation, Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) releases its total number of shares outstanding as well as its voting rights as of September 1, 2025:
Total number of shares outstanding:
92,185,473 ordinary shares
6,419 Preferred Shares 2016
7,581 Preferred Shares 2017
Total number of theoretical voting rights (1):
Total number of exercisable voting rights (2):
92,962,943
92,944,368
(1) The total number of theoretical voting rights (or “gross” voting rights) is used as the basis for calculating the crossing of shareholding thresholds. In accordance with Article 223-11 of the AMF General Regulation, this number is calculated on the basis of all shares to which voting rights are attached, including s...
|
|
|
23.05.25 - 07:00
|
Outcome of Innate Pharma′s 2025 Annual General Meeting (Business Wire)
|
|
|
MARSEILLE, France--(BUSINESS WIRE)--#AG--Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) announced the voting results of its shareholders at the Annual General Meeting (“AGM”), which took place on May 22, 2025, in Marseille. All resolutions were voted.
A total of 114 votes were cast out of a total of 43,447,237 shares giving right to 43,535,215 voting rights, representing a quorum of 47,14%.
Following the approval of its shareholders at the Annual General Meeting held on May 22, 2025, the Company has transitioned from an Executive Board and Supervisory Board corporate governance structure to a Board of Directors structure with a Chief Executive Officer.
New Governance Structure
The newly appointed Board of Directors comprises:
-
Mrs. Irina Staatz-Granzer;
-
Mr. Jonathan Dickinson;
-
Mrs. Véronique Chabernaud;
-
Mrs. Pascale Boissel;
-
Mrs. Sally Bennett;
-
Mr. Christian Itin;
-
Mr. Marty J. Duvall; and
-
Bpifrance Participations, represented b...
|
|
|
19.05.25 - 07:06
|
Innate Pharma Highlights Abstracts Selected for ASCO 2025 Annual Meeting (Business Wire)
|
|
|
Long term follow-up results of TELLOMAK Phase 2 trial in Sézary syndrome and mycosis fungoides
Trial in Progress poster on IPH4502, Innate's differentiated ADC in development in advanced solid tumors expressing Nectin-4
AstraZeneca to present a poster on updated results from the Phase 2 trial NeoCOAST-2 in resectable NSCLC
MARSEILLE, France--(BUSINESS WIRE)--#ANKET--Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) announced today that four abstracts with Innate's drugs in clinical development have been accepted for the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting, taking place May 30-June 3, 2025 in Chicago, Illinois.
“We are looking forward to participating in the ASCO Annual Meeting 2025, where four abstracts with Innate's drugs in clinical development have been selected. In particular, we are pleased to share the long-term follow-up data from the TELLOMAK Phase 2 study, which underscores our continued commitment to advan...
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
